Stockscreener 앱 받기
10.15
5.40%
0.52
시간 외 거래:
10.10
-0.05
-0.49%
전일 마감가:
$9.63
열려 있는:
$11.11
하루 거래량:
3.06M
Relative Volume:
5.38
시가총액:
$510.79M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.606
EPS:
-6.32
순현금흐름:
$-194.72M
1주 성능:
-12.20%
1개월 성능:
-8.56%
6개월 성능:
-36.52%
1년 성능:
-47.92%
1일 변동 폭
$9.93
$11.38
1주일 범위
$9.58
$12.11
52주 변동 폭
$8.535
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RGNX | 10.15 | 510.79M | 89.04M | -241.08M | -194.72M | -6.32 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive
REGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - Seeking Alpha
What's Going On With REGENXBIO Shares Monday? - Benzinga
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch
Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Regenxbio down 13% ahead of data readout for muscular dystrophy asset - Seeking Alpha
REGENXBIO (NASDAQ:RGNX) Shares Gap UpWhat's Next? - MarketBeat
Redmile Group, LLC Increases Stake in Regenxbio Inc - GuruFocus.com
5 Analysts Have This To Say About Regenxbio - Benzinga
REGENXBIO's (RGNX) Overweight Rating Reaffirmed at Morgan Stanley - MarketBeat
REGENXBIO to Present First Functional Data for Novel Duchenne Gene Therapy RGX-202 | RGNX Stock News - StockTitan
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World
REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World
HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat
HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey
REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... - Yahoo Finance
Regenxbio: Q3 Earnings Snapshot - The Washington Post
RegenXBio Reports Progress Amid Revenue Decline - TipRanks
Regenxbio Inc earnings missed by $0.05, revenue topped estimates - Investing.com Australia
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates - StockTitan
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Regenxbio Inc Holdin - GuruFocus.com
Sorrento Therapeutics (OTCMKTS:SRNEQ) & REGENXBIO (NASDAQ:RGNX) Financial Survey - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan
When (RGNX) Moves Investors should Listen - Stock Traders Daily
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - cnhinews.com
Assenagon Asset Management S.A. Lowers Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $9.1 amid market challenges By Investing.com - Investing.com South Africa
RGNX stock touches 52-week low at $9.1 amid market challenges - Investing.com
SG Americas Securities LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
How the (RGNX) price action is used to our Advantage - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Chardan Capital - Defense World
The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - MarketBeat
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):